MorphoSys (ETR:MOR) received a €96.00 ($111.63) price objective from equities research analysts at Independent Research in a note issued to investors on Thursday. The brokerage currently has a “neutral” rating on the stock. Independent Research’s price target points to a potential upside of 11.76% from the stock’s current price.

A number of other research firms have also recently issued reports on MOR. Commerzbank set a €107.00 ($124.42) target price on MorphoSys and gave the company a “neutral” rating in a research report on Friday, November 16th. Oddo Bhf set a €116.00 ($134.88) target price on MorphoSys and gave the company a “buy” rating in a research report on Monday, November 19th. Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys and gave the company a “sell” rating in a research report on Monday, November 26th. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys and gave the company a “buy” rating in a research report on Thursday, December 6th. Finally, Deutsche Bank set a €130.00 ($151.16) target price on MorphoSys and gave the company a “buy” rating in a research report on Monday, December 10th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. MorphoSys has an average rating of “Hold” and an average target price of €101.30 ($117.79).

MOR stock opened at €85.90 ($99.88) on Thursday. The stock has a market capitalization of $2.71 billion and a P/E ratio of -95.98. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €124.90 ($145.23). The company has a debt-to-equity ratio of 0.01, a current ratio of 11.51 and a quick ratio of 11.21.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Featured Story: How a Strangle Strategy is different from a Straddle Strategy

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.